Nasdaq grts.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...Shares of NASDAQ GRTS opened at $1.37 on Friday. The company has a market capitalization of $130.62 million, a price-to-earnings ratio of -1.10 and a beta of 0.62. The company has a debt-to-equity ...Follow. EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

EMERYVILLE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 76.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth ...EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...

Aug 1, 2023 · Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...

GRTS: Get the latest Gritstone Oncology stock price and detailed information including GRTS news, historical charts and realtime prices. Indices Commodities Currencies StocksEMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...GRTS Earnings Date and Information. Gritstone bio last posted its earnings data on November 8th, 2023. The reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. The firm earned $1.57 million during the quarter, compared to analysts' expectations of $2.10 million.Find the latest Financials data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.WebEMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Shares of NASDAQ GRTS opened at $1.37 on Friday. The company has a market capitalization of $130.62 million, a price-to-earnings ratio of -1.10 and a beta of 0.62. The company has a debt-to-equity ...Gritstone bio ; Status. IPO in 2018 (NASDAQ: GRTS) ; Year of Investment. 2015 ; Strategy. Life Sciences ; Location. Bay Area, California ...EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio stock quote and GRTS charts. Latest stock price today and the US's most active stock market forums.Sep 16, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the …WebGritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago (Simply Wall St.) Jun-13-23 07:00AM Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) Jun …

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical ...Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Find the latest on short interest for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.WebGRTS Historical Data. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ...Gritstone Bio ($NASDAQ:GRTS) is a clinical-stage immuno-oncology company focused on developing neoantigen cancer vaccines to treat patients with solid tumors.Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenueGritstone bio stock quote and GRTS charts. Latest stock price today and the US's most active stock market forums.Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and ... Home GRTS • NASDAQ. add. Share. GRTS. $1.88. After Hours: $1.93. ( 2.66%)+ ...

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ...

A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Aug 31, 2023 · As of August 31, 2023, the average one-year price target for Gritstone Bio is 8.77. The forecasts range from a low of 2.02 to a high of $21.00. The average price target represents an increase of ... Gritstone Bio Inc (NASDAQ:GRTS) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% ...EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.May 31, 2022 · EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... Vaccine-developer Gritstone bio ( NASDAQ: GRTS) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in ...Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.

EMERYVILLE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today shared positive Phase 1 clinical data from the first cohort (10 µg dose of CORAL self-amplifying mRNA …Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.The average trading volume of GRTS on November 15, 2023 was 2.18M shares. GRTS) stock’s latest price update. Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has gone rise by 8.72 in comparison to its previous close of 1.37, however, the company has experienced a -11.86% decrease in its stock price over the last five trading days.Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious …WebInstagram:https://instagram. best insurance companies for umbrella policiespenny stock trading websitesballard power systems incis forex trading legal (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ... 24 days ago ... price for 1964 kennedy half dollar401k changes 2024 Aug 10, 2022 · Celebrations may be in order for Gritstone bio, Inc. (NASDAQ:GRTS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ... profiting with forex Dec 13, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.